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Abstract
While genetic lesions responsible for some Mendelian disorders can be rapidly discovered through 
massively parallel sequencing (MPS) of whole genomes or exomes, not all diseases readily yield 
to such efforts. We describe the illustrative case of the simple Mendelian disorder medullary cystic 
kidney disease type 1 (MCKD1), mapped more than a decade ago to a 2-Mb region on 
chromosome 1. Ultimately, only by cloning, capillary sequencing, and de novo assembly, we 
found that each of six MCKD1 families harbors an equivalent, but apparently independently 
arising, mutation in sequence dramatically underrepresented in MPS data: the insertion of a single 
C in one copy (but a different copy in each family) of the repeat unit comprising the extremely 
long (~1.5-5 kb), GC-rich (>80%), coding VNTR in the mucin 1 gene. The results provide a 
cautionary tale about the challenges in identifying genes responsible for Mendelian, let alone more 
complex, disorders through MPS.
Medullary cystic kidney disease (MCKD) type 1 (OMIM 174000) is a rare disorder 
characterized by autosomal dominant inheritance of tubulo-interstitial kidney disease1. 
Affected individuals variably require dialysis or kidney transplantation in the third to 
seventh decade of life. Diagnosis of MCKD1 in patients is complicated by the unpredictable 
progression of kidney disease, the absence of other specific clinical manifestations, and the 
high frequency of mild kidney disease in the general population2. Nonetheless, the disease 
has been compellingly and consistently mapped to a single autosomal locus at 1q213-7. 
Attempts to identify the mutated gene(s), however, have not been successful4.
The advent of massively parallel sequencing (MPS) technologies has made exhaustive 
sequencing of genomic regions a viable approach to the identification of genes responsible 
for rare Mendelian diseases caused by high penetrance mutations8,9. Yet, there is also a 
growing recognition that using MPS to discover disease genes is not always straightforward. 
Here, we report that MCKD1 is caused by an unusual class of mutations, recalcitrant to 
detection by MPS. The process of identifying the MCKD1 causal variation is of particular 
interest for human genetics, because it highlights important challenges in using current MPS 
for gene discovery.
Linkage analysis was performed on six likely MCKD1 pedigrees (Online Methods, 
Supplementary Fig. 1 and Supplementary Table 1), and in all families the phenotype showed 
perfect co-segregation with a single 2-Mb segment of chromosome 1 (Fig. 1). We examined 
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the genotype data for evidence of copy-number variation in the critical interval, but found 
only two common copy-number polymorphisms, neither of which segregated with disease. 
Looking at the longest stretches of allelic identity within pairwise comparisons of the 
pedigrees’ phased risk-haplotypes, we also found no obvious ancestral haplotype shared by a 
significant fraction of the families (beyond the background LD in the general population). 
This result suggested that the families carried independently occurring mutations, consistent 
with the families’ diverse ancestries.
To search for mutations, we employed whole exome-, regional-capture- and whole genome 
sequencing (Online Methods). We selected two affected individuals from each pedigree for 
sequencing, chosen, where possible, to share only a single haplotype (the risk haplotype) 
across the linkage region. In protein-coding regions, we found only two rare (<1% in 1000 
Genomes Phase I data10), non-silent point variants (SNPs or small indels) shared by both of 
the affected individuals in any pedigree: each was in a different gene and each in a different 
pedigree. This finding is consistent with the expected background rate for 75 genes in six 
independent risk chromosomes given the presence of 100-200 rare coding variants in a 
typical genome10. In the context of perfect segregation of the phenotype, near-complete 
coverage of the coding bases in the linked region and the experience with other Mendelian 
diseases, we had expected to find a gene harboring rare coding variants in multiple families. 
To our dismay, we found no such evidence.
We next examined the non-coding regions, but found no regional clustering of segregating 
rare variants. We searched for any large structural variation (hundreds of bases or larger) 
such as deletions, insertions, duplications and inversions. All variants identified in this 
manner either failed to segregate with disease or were found at appreciable levels in control 
populations.
At this point, we concluded that the causal mutation(s) in MCKD1 were either located in a 
subregion that was recalcitrant to sequencing or represented a novel mutational mechanism. 
We considered the possibility that MCKD1 might be due to expansions in a coding VNTR 
sequence, because recurrent mutations at coding VNTRs have been documented as the cause 
of many genomic disorders11 and because massively parallel sequencing data might not 
readily reveal such an expansion.
We used SERV (Sequence-based Estimation of minisatellite and microsatellite Repeat 
Variability)12 to identify highly variable tandem repeats (VNTRs) in or overlapping with 
coding regions of five genes contained within the disease-linked interval: KCNN3, EFNA3, 
ASH1L, MEF2D and MUC1. Candidate VNTRs in the first four genes were found either to 
be non-polymorphic or to show no notable expansion in affected individuals (relative to 
family members not sharing the risk haplotype and to CEPH family samples), based on 
direct assays of length by PCR.
The MUC1 VNTR was particularly difficult to assay: it consists of many (20-12513,14) 
copies of a large repeat unit (60 bases) with very high GC-content (>80%). We ultimately 
assayed the VNTR by Southern blot and confirmed results with long-range PCR (Online 
Methods). In our patient samples, VNTR lengths were consistent with published 
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descriptions and were not expanded on risk chromosomes, excluding VNTR length as 
pathogenic. MUC1 remained particularly interesting as the only gene in the critical region 
displaying transcripts with kidney-specific expression, based on RNASeq data from an adult 
control individual (unrelated to this study). MUC1 encodes mucin 1, a transmembrane 
protein expressed on the apical surface of most epithelial cells, providing (amongst other 
functions) a protective barrier to prevent pathogens from accessing the cell surface. The 
protein possesses a heavily glycosylated extracellular domain containing the VNTR and an 
SEA module with a cleavage site for release of the extracellular domain, which then binds 
noncovalently to the transmembrane domain17,19 (Fig. 2a).
We considered the possibility that MCKD1 might be caused by point mutations within the 
MUC1 VNTR missed due to poor sequence coverage because (i) it was excluded from 
whole-exome and regional-capture probes due to its low-complexity and extreme sequence 
composition (and also because it is rarely annotated as coding sequence) and (ii) it was 
dramatically underrepresented in quality-filtered data from the whole-genome sequence, 
likely due to its GC-richness and homopolymer content. Because the human reference 
sequence appeared to significantly underrepresent this region (hg19 predicts a VNTR length 
far smaller than the published range or that observed in any of our samples, including 
controls), we undertook to clone and then reconstruct the VNTR alleles of several affected 
individuals and a CEPH trio; we subcloned, Sanger sequenced and performed de novo 
assembly for each (Online Methods and e.g. Fig. 2b-d).
We found a number of point variants in the VNTR assemblies, but, with one exception, they 
either did not segregate with the risk haplotype or were present in the alleles of the CEPH 
trio and/or unaffected chromosomes. However, we found one variant consistent with disease 
segregation: the insertion of a single C (relative to the coding strand of MUC1) within a 
stretch of seven C’s occurring at positions 53-59 in a single copy of the canonical 60-mer 
repeat (e.g. Fig. 2e). All six families carried such +C insertions, which appear to have arisen 
independently based on the different overall sizes of the VNTR, different local sequence 
contexts and different precise repeat units harboring the insertion (Supplementary Figs 2 and 
3).
The frameshift caused by the insertion predicts a mutant protein that contains many copies 
of a novel repeat sequence (obtained by shifted translation of the VNTR) but which lacks, 
owing to a novel stop codon shortly beyond the VNTR terminus, the downstream SEA self-
cleavage module and both transmembrane and intracellular domains characteristic of the 
normal MUC1 precursor protein (Fig. 2a).
Because discovery of the +C insertion required considerable labor and time, we sought to 
develop a simple and robust genotyping assay to enable larger population screening. We 
designed a probe-extension assay (Online Methods and Fig. 3a) capable of distinguishing 
reference and mutant MUC1 VNTR repeat units, making use of MwoI (which selectively 
cleaves the reference sequence) to increase the stoichiometric ratio of mutant:reference 
repeat units.
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We typed all samples collected from the six MCKD1 families used for linkage analysis, 
including 62 phenotypically affected and 79 unaffected relatives (Fig. 3b-c), and over 500 
control individuals from CEU, Japanese, Chinese, Yoruba and Tuscan HapMap3 
populations (Fig. 3d). The genotyping assay was perfectly concordant with sequencing 
results, and full genotyping of all family members showed that the insertion segregated 
perfectly with each family’s risk haplotype and yet was not seen in any of the 500 HapMap 
samples.
Overall, the genotyping results provide strong evidence that the +C insertions are the high-
penetrance genetic lesion that leads to development of MCKD1. As a statistical association, 
the significance of this observation can only be approximated, but it is clearly far less than 
the reciprocal of the number of bases in the genome (+C seen on 6/6 risk chromosomes vs. 
0/1000 HapMap chromosomes). Furthermore, this observation is robust to population 
structure considerations since the mutations have arisen independently.
To explore the broader impact of MUC1 mutations, we genotyped affected and unaffected 
individuals from 21 additional small MCKD families screened to be negative for known 
MCKD mutations (Supplementary Table 1), only one family of which had existing linkage 
information implicating 1q2115. In 13 of 21 families we found the presence of a +C insertion 
consistent with being a fully penetrant cause of disease, indicating a substantial role for 
MUC1 in MCKD1-like phenotypes.
Using antibodies raised against a peptide synthesized based upon the predicted mutant 
VNTR sequence, we found specific intracellular staining in epithelial cells of Henle’s loop, 
distal tubule and collecting duct of MCKD1 patients (Fig. 4a), which was absent in control 
kidney (Fig. 4b). Co-staining of patient and control tissue additionally with antibodies 
against normal MUC1 demonstrated the specificity of the MUC1-fs (our name for the 
predicted mutant protein) antibodies for the mutant protein, with diffuse and/or fine granular 
intracellular localization of the MUC1-fs protein in patient kidney (Fig. 4c), and also patchy 
co-localization of MUC1-fs and normal MUC1 signals on the apical membrane of collecting 
duct epithelial cells (Fig. 4c and 4d). Detailed image analysis of patient tissue (Fig. 4d) 
compared to control tissue (Fig. 4e) detected no intracellular co-localization of MUC1-fs 
and normal MUC1 proteins in patient tissue, but revealed puncti of colocalization in distinct 
plasmalemmal subdomains. Antibody to MUC1-fs did not stain normal kidney tissue.
This study highlights the fact that current MPS technology may not suffice to reveal disease 
mutations, even when linkage analysis conclusively pinpoints a critical region of a few 
megabases. Even if the insC event were not dramatically underrepresented in the quality-
filtered MPS data and even if the reference genome assembly had been accurate in this 
region, it still would have been difficult to detect this particular insertion event using typical 
alignment and variation-detection tools due to (1) the underlying variability of VNTR size 
within and across individuals, (2) the inability to uniquely place reads within the VNTR, 
given current MPS read lengths, and (3) the fact that the mutant:reference allelic balance is 
skewed far from the expected 1:1 of a typical heterozygous variant.
Kirby et al. Page 5
Nat Genet. Author manuscript; available in PMC 2014 January 24.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
The precise nature of the MCKD1 mutations is notable. Curiously, each independently-
arising event is essentially the identical single-base insertion at the same position within one 
of the repeat units of the VNTR. Yet, insertions at many locations or other events (such as 
single-base deletions) would also result in out-of-frame translation of MUC1 and/or novel 
stop codons. Possible explanations for the consistently observed mutation include: (1) this 
insertion event is strongly favored due to mutational mechanism, (2) other events (eg. delC) 
are selected against, (3) other events (eg. delC) are benign and not associated with MCKD1, 
and (4) other MUC1 mutations exist but are undersampled here.
The identified mutation and the associated genotyping assay provide a screening tool for 
younger members of families in which MCKD1 has been previously diagnosed, as well as a 
diagnostic tool for sporadic cases. They also alleviate the challenge for living relative kidney 
donation, as potential donor family members have not known their status as unaffected or 
(yet-to-be) affected. Much work, however, remains to be done to elucidate the specific 
mechanism of pathogenesis of the MUC1 mutant protein. We note that knock-out studies 
indicate that the MUC1 gene is not essential in mice16 and support a possible dominant-
negative and/or gain-of-function mode of action for the human MUC1 mutation. Together 
with the dominant and late-onset nature of the disease, this raises the possibility of 
preventative or therapeutic approaches based on treatments that decrease expression of the 
MUC1 gene or splice out its single VNTR-encoding exon.
ONLINE METHODS
Family collection and criteria for diagnosis of affected status
The six analyzed families with autosomal dominant tubulointerstitial kidney disease were 
among a larger group referred for evaluation. Each showed a clinical phenotype highly 
suggestive of MCKD1 and lacked UMOD or REN mutations. All had previously 
demonstrated evidence of linkage to chromosome 1. Written informed consent was obtained 
from all participants and the study was approved by the Wake Forest School of Medicine 
Institutional Review Board. Medical records were reviewed and peripheral venous blood 
samples were obtained for DNA isolation and laboratory determinations. Full diagnostic 
methods and clinical summaries are described in Supplementary Note.
Linkage and CNV analysis
Family members were genotyped on the Affymetrix 6.0 platform. Whole Affymetrix arrays 
with genotype call rates < 88% were excluded from analysis, as were samples which yielded 
low OD measurements (indicating poor sample performance during laboratory steps). 
Further, markers were excluded for which probe sequences showed excess genomic 
homology or potential for significant G-quartet formation (those probe sequences for which 
either allele contained at least three consecutive G’s).
Particularly large pedigrees (>24 bit complexity) were divided into branches where required 
by computational constraints. LD-independent marker maps were separately created for each 
pedigree/branch, choosing single, well-typed, informative markers from LD-defined bins of 
SNPs based on phased, population-specific HapMap data (hapmap.org, release 22). Markers 
which showed no-call rates > 10% or any Mendelian inheritance errors within a pedigree/
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branch were excluded from specific pedigree/branch analyses. Additionally, markers were 
required to be spaced at least 0.1 cM apart according to published sex-averaged 
recombination positions (affymetrix.com).
All expected intra-pedigree relationships were confirmed from pairwise IBD estimates using 
PLINK software18 and similarly derived marker sets; however, markers for PLINK were 
selected agnostic to their being polymorphic within a pedigree/branch so as not to skew IBD 
calculations. Merlin software19 was used to remove any likely genotyping errors which did 
not violate Mendelian inheritance rules, and then to perform parametric linkage under a rare, 
autosomal-dominant model using population-specific allele frequencies (affymetrix.com).
Linkage mapping was performed using the Merlin package under a rare autosomal-dominant 
model. Scores were combined across pedigrees/branches by summing LOD values, linearly 
interpolating scores between marker locations as required. The consistency of the alleles 
carried on the segregating risk haplotype was confirmed across pedigree branches.
The boundaries of the linked region were refined by searching all well-typed markers -- 
including many that were dropped solely to eliminate markers in LD from the linkage 
calculations -- for instances where affected members within the same pedigree shared no 
alleles IBD (by virtue of being homozygous for opposite alleles – for example, one having 
genotype AA and another CC). Such markers necessarily lie outside the critical linkage 
interval.
Affymetrix 6.0 intensity data were used by Birdsuite software20 to analyze copy-number 
variation.
Large-scale sequencing
Because the critical region contains more than 170 separate transcript annotations 
comprising over 75 RefSeq genes, amplicon-based resequencing of genic regions was 
initially not considered. Of the 12 sequenced individuals, whole-genome sequencing was 
performed on 11 of these individuals (~25-fold coverage on average), whole-exome 
sequencing on 11 individuals (~180-fold coding-sequence coverage on average) and 
regional-capture sequencing on 5 individuals (~220-fold coverage on average). Sequence 
processing is described in Supplementary Note. For all but three of the RefSeq genes, at 
least 99% of the coding bases were covered at ≥10-fold in each pedigree. Further, 98% of 
non-coding bases were covered at ≥10-fold in each pedigree.
As candidates for being pathogenic MCKD1 mutations, we considered any non-reference 
allele present in both affected individuals of any pedigree and with a population frequency 
≤1%10. Non-coding regions were analyzed similarly.
To discover potential structural variation at the chromosome-1 locus, we ran Genome 
STRiP21 on the sequenced individuals and on a control population of 32 Finnish genomes 
sequenced at low coverage by the 1000 Genomes Project10 (Supplementary Note).
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MUC1-VNTR Southern blot analysis
Genomic DNA (5-8 μg) was digested with 100 u HinfI (NEB). Digests were run on a 0.8% 
agarose gel, transferred to a BrightStar Plus Nylon membrane (Ambion) and hybridized 
overnight at 65°C to a quadruply biotinylated synthetic 100mer oligonucleotide probe PS1 
(Supplementary Table 3) (IDT) present at 2 ng/ml in SuperHyb hybridization solution 
(Ambion) supplemented with 100 μg/ml sonicated salmon sperm DNA (Stratagene). After a 
final high-stringency wash at 65°C in 0.2x SSC and 0.1% SDS, membrane-bound biotin was 
detected by a BrightStar BioDetect kit (Ambion).
MUC1-VNTR long-range PCR
The long-range PCR protocol was adapted from Fowler et al.14. Briefly, 7-μL PCR reactions 
contained 15 or 30 ng genomic DNA, 1.75 pmol of PS2 and PS3 primers (Supplementary 
Table 3), 5% DMSO, 625 μM of each dNTP, 1x reaction buffer with 3 mM MgCl2, and 0.25 
u DyNAzyme EXT DNA polymerase (Finnzymes). Thermocycling on GeneAmp 9700 
instruments (ABI) was as follows: initial denaturation (90 s at 96°C); 22 or 27 cycles (40 s 
at 96°C, 30 s at 65°C, 6 min at 68°C) and final extension (10 min at 68°C).
MUC1-VNTR sequencing and assembly
For selected individuals, we cloned gel-purified long-range-PCR products containing the 
full-length VNTR. Allele sizes derived from Southern blots and long-range PCR, together 
with known haplotype sharing between individuals in the same pedigree, in most cases 
permitted the identification of which MUC1 VNTR allele was part of the segregating risk 
haplotype (e.g. Fig. 2b and c). In a few cases, the sizes of the risk and non-risk VNTR allele 
were nearly the same, precluding physical separation of the two alleles prior to molecular 
cloning. Using transposon hopping and capillary sequencing, we then sequenced clones 
from each allele (Supplementary Note).
Because the region is exceptionally repetitive and because the read data contain both PCR 
errors and sequencing errors (exacerbated by the extreme GC content of the repeat), we 
developed a special assembly algorithm that could distinguish bona fide genomic differences 
from errors (Supplementary Note). Given the repetitive sequence content, not all assemblies 
were complete or unambiguous. Instead, some assembly frameworks suggested multiple 
possible resolutions across areas of uncertainty, forming full networks of possible solutions 
for a particular allele.
Supplementary Table 2 summarizes the key properties of the assemblies (example shown in 
Figure 2d), and Supplementary Figures 3 and 4 provide the sequence for those unique alleles 
(three risk and eight non-risk) where the assembly was fully or almost fully resolved. 
Supplementary Figure 5 illustrates the notation of graph assembly in a scenario where an 
allele could not be fully and unambiguously reconciled. We assembled each allele separately 
and independently. In all situations where two alleles were expected to be identical by 
haplotype sharing and where the assemblies were fully resolved, the assemblies were indeed 
identical – thus increasing our confidence that the assemblies were correct.
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Genotyping of MUC1 +C insertion event
Genomic DNA was first over-digested using restriction endonuclease MwoI which 
selectively cleaves the reference repeat-unit sequence (GCCCCCCCAGC), while leaving 
intact repeat units containing the +C insertion (GCCCCCCC*C*AGC). Tailed primers 
nested within the 60-bp repeat were then used to PCR amplify the remaining intact VNTR 
fragments, thus enriching for insertion-containing fragments over reference-sequence 
background. PCR products were then re-digested with MwoI for a second round of 
enrichment. A 20-bp probe was then designed just upstream of the insertion site, and probe 
extension was performed using a high fidelity DNA polymerase and a nucleotide 
termination mix containing dATP, ddCTP and ddGTP. Following probe extension, reaction 
products were separated and sized by MALDI-TOF mass-spectrometry using the Sequenom 
MassArray platform. Spectra were then assessed for the presence of peaks corresponding to 
the mutant repeat-unit extension-product (at 5,904.83 daltons) and the reference repeat-unit 
extension-product (at 6258.06 daltons).
Specifically, 100 μg of genomic DNA was digested in a 25-μL reaction volume for 16 hours 
using 5 units of MwoI restriction endonuclease (New England Biolabs) with supplemental 
additions of 5 units of enzyme at hours 3 and 15. Digestion reactions were then cleaned 
using 50 μL AmPure beads according to manufacturers protocol (Agencourt, Beverly, MA), 
and digested DNA was eluted in 25 μL of nuclease-free water. Remaining intact VNTR 
fragments were PCR-amplified using 1X HotStart buffer, 1.0 mM MgCl2 (to supplement 
MgCl2 already in buffers), 0.8 mM dNTPs, 0.8 units of HotStart Taq Plus (Qiagen) and 0.2 
μM forward and reverse primers PS6 and PS7 (Supplementary Table 3) in a 25-μL reaction 
volume. PCR cycling conditions were: one hold at 95°C for 5 min; 45 cycles of 94°C for 30 
sec, 67°C for 30 sec, 72°C for 1 min; followed by one hold at 72°C for 10 min. PCR 
reactions were cleaned using 50 μL AmPure beads, and amplicons were eluted in 25 μL 
nuclease-free water. A second round of MwoI digestion was performed again for 16 hours 
with 5 units of enzyme added at hours 0, 3 and 15. Digestion reactions were cleaned using 
50 μL AmPure beads and product was eluted in 6.2 μL of nuclease-free water.
Using 5.2 μL of the digested eluate as template, probe extension was performed using 1X 
HotStart buffer, 0.6 mM MgCl2 (to supplement MgCl2 already in buffers), 1.7 μL SAP 
buffer (Sequenom, San Diego, CA), 0.2 mM each of nucleotides ddGTP, ddCTP and dATP; 
0.7 units of Thermo Sequenase DNA polymerase (Amersham) and 0.6 μM of extension 
probe PS8 (Supplementary Table 3) in a 10-μL reaction volume. Probe extension was 
performed on a 384-well ABI GeneAMP 9700 and cycling conditions were: one hold at 
94°C for 2 min 55 cycles of 94°C for 5 sec, 52°C for 5 sec, 72°C for 5 sec; followed by one 
hold at 72°C for 7 min. Reactions were then de-salted by addition of a cation-exchange 
resin, and ~7 nL of purified extension reaction was spotted onto a SpectroChip (Sequenom) 
containing matrix 3-hydroxypicoloinic acid. Arrayed reactions were then analyzed by 
matrix-assisted laser desorbtion/ionization-time of flight (MALDI-TOF) on a Compact mass 
spectrometer (Sequenom/Bruker).
Assay results were clear enough to assign genotypes based on simple inspection of XY 
scatterplots depicting log-transformed reference- and mutant-repeat-unit intensities 
(log10(1.0+peak height)). Samples showing log-transformed intensities < .25 for both alleles 
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were considered failed assays. Similarly, results from whole-genome-amplification samples 
or samples with low DNA concentrations were typically considered unreliable and 
discarded.
Antibody generation and kidney immunostaining
Immunodetection of MUC1-fs was performed with custom-prepared rabbit antibodies (PA4 
302) raised against the peptide SPRCHLGPGHQAGPGLHRPP, representing the predicted 
mutant VNTR unit (Open Biosystems, Huntsville, AL; diluted 1:1000 in 5% BSA in PBS). 
The normal MUC1 protein was detected with monoclonal mouse anti-human Epithelial 
Membrane Antigen (EMA) mouse monoclonal antibody (DAKO, Glostrup, Denmark; 
diluted 1:400 in 5% BSA in PBS). Detection of bound primary antibody was achieved using 
either Dako EnVision + TM Peroxidase Rabbit Kit (Dako) or System-HRP labeled Polymer 
Anti-mouse (DAKO), for rabbit or mouse antibodies, respectively, with 3,3′-
diaminobenzidine as substrate.
Paraformaldehyde-fixed human kidney biopsies were analysed. The specificity of antigen 
detection was always ascertained by omission of the primary antibody-binding step.
For immunofluorescence analysis, PA4 302 antibody was diluted 1:200 in 5% BSA in PBS 
and EMA antibody was diluted 1:10 in 5% BSA in PBS. Fluorescence detection used 
species-specific secondary antibodies. Alexa Fluor® 488 goat-anti rabbit IgG and Alexa 
Fluor® 568 goat-anti mouse IgG (Molecular Probes, Invitrogen, Paisley, UK). Nuclei were 
stained with 4’,6-diamidino-2-phenylindole (DAPI). Prepared slides were mounted in 
Immu-Mount fluorescence mounting medium (Shandon Lipshaw, Pittsburgh, PA) and 
analyzed by confocal microscopy.
XYZ images sampled according to Nyquist criterion were acquired using a TE2000E C1si 
laser scanning confocal microscope, Nikon PlanApo objective (40x, N.A.1.30), 488 nm and 
543 nm laser lines and 515 +/-15 nm and 590 +/-15 nm band pass filters. Images were 
deconvolved using the classic maximum likelihood restoration algorithm in Huygens 
Professional Software (SVI, Hilversum, The Netherlands). Colocalization maps employing 
single pixel overlap coefficient values ranging from 0-1 were created using Huygens 
Professional Software. The resulting overlap coefficient values are presented as pseudo-
color (scale is shown in corresponding figure lookup tables).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Linkage of six MCKD1 families to chromosome 1
LOD curve shows the combined linkage-score of six MCKD1 pedigrees across 12 Mb of 
chromosome 1, with the peak score well above the threshold of 3.6 for genome-wide 
significance17. Red X’s mark the locations of opposite-allele homozygous genotype calls 
between affected members within each pedigree and highlight regions where affected 
individuals de facto share no alleles IBD, thereby delineating genomic segments unlikely to 
harbor causal variation. The shaded region (hg19:chr1:154,370,020–156,439,000) was 
considered most likely to contain any causal mutations, bounded on each side by 
recombination breakpoints in two different pedigrees.
Kirby et al. Page 12
Nat Genet. Author manuscript; available in PMC 2014 January 24.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. Discovery of +C insertion within MUC1 coding VNTR
(a) The major domains of the full-length MUC1 precursor protein are shown: N-terminal 
signal sequence, VNTR, SEA module (where cleavage occurs), transmembrane domain, and 
C-terminal cytoplasmic domain. Based on fully and unambiguously assembled VNTR 
alleles, the frameshift caused by insertion of a C in the coding strand (as described in the 
main text) is expected to introduce a novel stop codon shortly beyond the VNTR domain. (b 
and c) Where possible, knowledge of segregating phased SNP-marker haplotypes was used 
to select for de novo VNTR sequencing and assembly of those individuals sharing only a 
single haplotype across the region, as this aided identification of the VNTR allele 
segregating with the shared risk haplotype. (d and e) Independent de novo assembly of the 
shared VNTR allele in two individuals from family 4 shows exactly identical complete 
sequence, with the seventh 60-base unit (red X) out of 44 containing a +C insertion event. 
The assembly is oriented relative to the coding strand of MUC1 and covers bases 
chr1:155,160,963-155,162,030 (hg19). Each unique 60-base repeat segment is represented 
by a different letter or number (Supplementary Fig. 2). (e) Translational impact of +C 
frameshift.
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Figure 3. Detection of MUC1 +C insertion by probe-extension (PE) assay
(a) Exemplar electropherograms for the MUC1-VNTR +C-insertion PE assay (Online 
Methods) performed on homozygous reference-allele and heterozygote samples. (b) Allele-
intensity scatterplot for large linkage family 2. X-axis values correspond to the detected 
intensity at the mass of the +C PE product, while Y-axis values reflect that of the reference 
repeat-unit extension product. Datum coloring reflects MCKD1 diagnosis: blue = unaffected 
(or HapMap samples), red = affected, white = unknown. Individuals known to carry the 
linkage-analysis risk haplotype are represented by “+”, while other family members are 
depicted as dots. (c) Allele-intensity scatterplot for all MCKD1 linkage families. Samples 
having log-transformed intensities below 0.25 for both alleles were excluded as failed 
assays. WGA and low DNA-concentration samples were also excluded for underperforming. 
(d) Allele-intensity scatterplot for HapMap samples together with selected positive controls 
(MCKD1 individuals known to carry the insertion).
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Figure 4. Immunohistochemical and immunofluorescence studies of MUC1-fs protein
In MCKD1 patients, MUC1-fs is expressed and present in renal epithelial cells of Henle’s 
loop, distal convoluted tubule, and collecting duct. (a) Strong intracellular staining of 
MUC1-fs protein in MCKD1 patient, and (b) absence of the specific staining in control; 
TALH - thick ascending limb of Henle’s loop; CD – collecting duct; PT – proximal tubule. 
(c) Immunofluorescence analysis showing diffuse and/or fine granular intracellular and 
membrane staining of MUC1-fs protein, and its partial colocalization with normal MUC1 in 
collecting duct of an MCKD1 patient. MUC1-fs staining is absent in control, and 
colocalization with normal MUC1 is therefore not detected. The values of fluorescent signal 
overlaps are transformed to a pseudo-color scale shown at right bottom in the corresponding 
lookup table. (d) Immunofluorescence analysis showing different intracellular localizations 
and partial sub-membrane colocalization of MUC1-fs and normal MUC1 proteins in 
collecting duct of MCKD1 patient. Note specific staining of both forms in distinct 
membrane microdomains. (e) Absence of MUC1-fs staining and characteristic membrane 
localization of normal MUC1 in control.
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